Recommended Strategies for Your Next Biomarker-Driven Clinical Trial

Precision for Medicine
(Precision for Medicine)

Authors: Tiziana Magnani, Senior Project Manager & Stephanie Jarjabka, Director, Project Management

Over the past decade, there has been a paradigm shift in drug development. The rise of next generation precision medicines have fueled a dramatic increase in biomarker-driven clinical trials, which seek to optimize the likelihood of study success by enrolling only those patients who are most likely to demonstrate benefit. However, incorporating biomarkers into clinical development can be challenging, and innovators must carefully consider strategies for ensuring the selection and seamless integration of fit-for-purpose biomarkers into their study designs. 

Precision for Medicine, a global CRO, is purpose-built around developing and executing biomarker-driven clinical trials. Based on the experience and feedback from our global project teams, who actively support cell and gene therapy studies and other biomarker-influenced trials, Precision offers the following strategies for overcoming 4 common challenges in biomarker-driven trials.  

1. Effective Patient Identification in Biomarker-Driven Clinical Trials Requires a Clear Study Concept at the Outset 

Common Challenge: Often, during early phase research, sponsors may still be tweaking planned biomarkers. This lack of clarity can impact patient identification, next-generation sequencing (NGS) testing, patient stratification, site selection, study timelines, and costs.

Precision’s Recommended Strategies:

  • Set up a pre-screening trial. Suppose you are still deciding among biomarkers and have a large immunotherapy pipeline. In that case, you may want to consider setting up a pre-screening trial to create a funnel of patients who can then be enrolled into randomized trials across your portfolio.  
     
  • Lock in your biomarkers at the beginning of your clinical trial. The market is competitive, and biopharmaceutical sponsors must move at lightning speed, but not locking in your biomarkers at the time of study start-up (with a CRO engaged) will lead to scope, budget, and site creep. If you are still deciding among biomarkers, this can inflate the patient totals in your trial, with knock-on effects on overall study cost due to increases in the number of sites needed, the equipment required, and other resources. Having a solid protocol and clear biomarker foundation is critical for avoiding unnecessary expenditures and study delays caused by inevitable protocol amendments. This sounds simple, but taking a few more weeks or months to lock in your biomarkers at the front end will save your organization precious time and possibly millions on the back end.  


2. Awareness of NGS Testing Standards at Planned Sites within the Target Countries

Common Challenge
: Harmonized NGS testing standards simply do not exist. The NGS testing standard done at an academic institution, such as MD Anderson, is going to differ dramatically from testing completed in a community-based hospital system – where it may or may not even be done on a routine basis. Similarly, testing will vary if performed at a large hospital in Paris versus one in rural France.  

Precision’s Recommended Strategies:

  • When evaluating site feasibility, ask about the standard NGS testing done by the site for patients in your targeted indication. In our experience, many sponsors prefer to be deeply involved in site identification and may have already initiated site outreach and selection activities prior to engaging with their CROs. It is not uncommon for sponsors to overlook the NGS testing standards question during their initial conversations with study sites. This oversight can adversely impact rapid start-up if further feasibility is required. 

    Including specific, detailed questions about NGS testing in your site feasibility evaluations will give you a more accurate and comprehensive assessment of that site’s enrollment potential. If your selected biomarker is included in the site’s standard NGS testing, the site may already have a database of known patients with that biomarker, which may lead to more rapid enrollment. If your biomarker is not included, enrollment at that site will likely be slower as the screening process will require additional testing. Understanding enrollment potential is critical for curating an effective and efficient group of trial sites from which to find the right patients, thus enabling you to hit your overall study timeline.  
     
  • Plan for more screening failures than you would with a non-biomarker-driven trial. In biomarker-driven trials, NGS testing is a necessary part of the screening process. Screening can be expensive, though, and the cost of screening failures must be accounted for in the study budget. The likelihood of screening failures—and the resultant budget impact—will depend on several factors, including your indication, the statistical incidence of your expressed biomarker, and the type of testing required, among others.  
     
  • Carefully vet and select your NGS testing laboratory partner. With the lack of NGS testing standards and differences in its “routine” application between hospitals globally and locally, this dramatically increases the importance and capabilities required of your selected NGS testing vendor. Sponsors and their CROs have to carefully consider the selected specialty labs capabilities and ensure that the logistics of sample collection, shipment, analysis, etc. must all be fully thought through and documented in an agreed plan for your study. 
     
  • Ensure the capabilities of your CRO align with your biomarker requirements. The growth of targeted treatments has increased the therapeutic importance of companion diagnostics. If your study requires a new assay or companion diagnostic, ensure that your selected CRO partner has the capability to support its development. Precision for Medicine is adept at supporting biopharmaceutical sponsors through the intricacies of companion diagnostic development, providing end-to-end expertise from specialty lab services and regulatory strategy to market access and commercialization. This is where a fully capable CRO, like Precision, can make a difference in your development to approval timeline. 


3. Efficient integration of biomarker data to support study and patient decision making. 

Common Challenge: Biomarker-driven clinical trials often involve more external data sources and thus require additional technologies to support data mapping and data integration. Turning data chaos into actionable insights is critical for supporting rapid decision-making at the screening stage and for informing treatment and maintenance, especially if your therapy is cell or gene based.  

Precision’s Recommended Strategy:

Implement a robust biomarker data management solution. Biomarker-driven trials generate large datasets across a wide range of assay modalities (see Figure 1), but the data often remains siloed. It is critical to break down and break through common data silos, so the full data picture can be leveraged to make crucial and time-sensitive decisions about a patient’s participation or status in an immunotherapy-focused clinical trial. Precision’s multiomic QuartzBio® data platform is designed to synthesize diverse biological data to reveal hidden insights—within and across studies.

Figure 1. Biomarker data management links the breadth and depth data generated in biomarker-driven trials, as described in Precision's use case, "From IHC to Immune Profiling: Managing Data Breadth and Depth to Inform On-Study Decisions."         (Precision for Medicine)


4. Sample management is critical to patient identification and selection in biomarker-driven trials.  

Common Challenge: Every sample collected in a biomarker-driven trial is vital to study success, especially if your therapeutic is cell-therapy based. Studies that do not have a well-thought-out logistics plan will have issues managing critical samples.  

Precision’s Recommended Strategy:

Assign a dedicated logistics coordinator to support the additional demands of your biomarker-driven clinical trial. The role of a logistics coordinator is to serve as the primary point of contact among the sites, the clinical research associates monitoring those sites, the specialty labs involved, and the manufacturing company when a cell therapy is involved. Having a dedicated logistics coordinator can be a difference-maker at the patient identification stage and during treatment.  

Pair your logistics coordinator with a virtual sample inventory management solution (vSIM). In studies like these, if your internal and external team members are left tracking samples via massive spreadsheets, then errors are likely. In addition, too much time is spent manually wrangling data across participating sites, labs, vendors and biorepositories. By pairing your logistics coordinator with a vSIM solution, like Precision QuartzBio®, you can gain centralized visibility into sample collection, processing, and storage status across siloed source systems for key stakeholders in your trial.  

Key Takeaway

The use of biomarkers to individualize treatment is a cornerstone of precision medicine. Successful incorporation of biomarkers for effective patient identification and selection requires careful planning. Working with a CRO who understands the nuances of biomarker-driven clinical trials ensures you have the support you need to realize the full potential of your study. At Precision for Medicine, we integrate clinical trial execution with deep scientific knowledge, specialized laboratory expertise, and advanced data sciences, helping innovators conquer their most complex work.

The editorial staff had no role in this post's creation.